Excitation of a Single Compound by Light and Ultrasound Enhanced the Long-Term Cure of Mice Bearing Prostate Tumors
-
Published:2023-06-25
Issue:13
Volume:24
Page:10624
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Cacaccio Joseph1, Durrani Farukh A.1, Kumar Ishaan1, Dukh Mykhaylo1, Camacho Susan1, Fayazi Zahra1, Sumlin Adam1, Kauffman Eric2, Guru Khurshid2, Pandey Ravindra K.1
Affiliation:
1. PDT Center, Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA 2. Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA
Abstract
Current treatment for prostate cancer is dependent on the stages of the cancer, recurrence, and genetic factors. Treatment varies from active surveillance or watchful waiting to prostatectomy, chemotherapy, and radiation therapy in combination or alone. Although radical prostate cancer therapy reduces the advancement of the disease and its mortality, the increased disease treatment associated morbidity, erectile dysfunction, and incontinence affect the quality of life of cancer survivors. To overcome these problems, photodynamic therapy (PDT) has previously been investigated using PhotofrinTM as a photosensitizer (PS). However, Photofrin-PDT has shown limitations in treating prostate cancer due to its limited tumor-specificity and the depth of light penetration at 630 nm (the longest wavelength absorption of PhotofrinTM). The results presented herein show that this limitation can be solved by using a near infrared (NIR) compound as a photosensitizer (PS) for PDT and the same agent also acts as a sonosensitizer for SDT (using ultrasound to activate the compound). Compared to light, ultrasound has a stronger penetration ability in biological tissues. Exposing the PS (or sonosensitizer) to ultrasound (US) initiates an electron-transfer process with a biological substrate to form radicals and radical ions (type I reaction). In contrast, exposure of the PS to light (PDT) generates singlet oxygen (type II reaction). Therefore, the reactive oxygen species (ROS) produced by SDT and PDT follow two distinct pathways, i.e., type I (oxygen independent) and type II (oxygen dependent), respectively, and results in significantly enhanced destruction of tumor cells. The preliminary in vitro and in vivo results in a PC3 cell line and tumor model indicate that the tumor specificality of the therapeutic agent(s) can be increased by targeting galectin-1 and galectin-3, known for their overexpression in prostate cancer.
Funder
RPCCC Support Grant Photolitec, LLC
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference48 articles.
1. Racial and ethnic differences in advanced-stage prostate cancer: The Prostate cancer outcome study;Hoffman;J. Natl. Cancer Inst.,2001 2. Racial differences in the diagnosis and treatment of prostate cancer;Pietro;Int. Neurourol. J.,2016 3. Patients’ perceptions of the negative effects following different prostate cancer treatments and the impact on psychological well-being: A nationwide survey;Lehto;Br. J. Cancer,2017 4. Debnath, S., Zhou, N., Laughlin, M.M., Rice, S., Pillai, A.K., Hao, G., and Dun, X. (2022). PSMA-targeting imaging and theranostic agents- current status and future perspective. Int. J. Mol. Sci., 23. 5. Sonodynamic Therapy: A review of the synergistic effects of drugs and ultrasound;Rosenthal;Ultrason. Sonochem.,2004
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|